Internal clamp for surgical procedures
One aspect of the present invention relates to a method of occluding a vascular site in a mammal, comprising the step of introducing into the vasculature of a mammal at or proximal to a surgical site, a composition comprising at least one optionally purified inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, thereby temporarily occluding a vascular site of said mammal, wherein said temporarily occluded vasculature site is kept in a substantially cylindrical shape.
1. A method of temporarily occluding a vascular site in a mammal comprising the steps of:
introducing into the vasculature of a mammal, at or proximal to a surgical site, a composition comprising at least one purified inverse thermosensitive polymer, wherein said at least one purified inverse thermosensitive polymer gels in said vasculature, thereby temporarily occluding said vascular site of said mammal; and
performing a surgical procedure.
2. The method of claim 1 , wherein said composition comprises at least one purified inverse thermosensitive polymer selected from the group consisting of poloxamers and poloxamines.
3. The method of claim 1 , wherein said at least one purified inverse thermosensitive polymer is selected from the group consisting of poloxamer 407, poloxamer 338, poloxamer 118, poloxamine 1107 or poloxamine 1307.
4. The method of claim 1 , wherein said at least one purified inverse thermosensitive polymer is poloxamer 407.
5. The method of claim 1 , wherein said temporarily occluded vascular site, at or proximal to a surgical site, is a substantially circular or substantially elliptical right cylinder, a substantially circular or substantially elliptical oblique cylinder, a substantially circular or substantially elliptical right truncated cone, or a substantially circular or substantially elliptical oblique truncated cone.
6. The method of claim 5 , wherein said composition comprises at least one purified inverse thermosensitive polymer selected from the group consisting of block copolymers, random copolymers, graft polymers, and branched copolymers.
7. The method of claim 5 , wherein said at least one purified inverse thermosensitive polymer is a polyoxyalkylene block copolymer.
8. The method of claim 5 , wherein said composition comprises at least one purified inverse thermosensitive polymer selected from the group consisting of poloxamers and poloxamines.
9. The method of claim 5 , wherein said at least one purified inverse thermosensitive polymer is selected from the group consisting of poloxamer 407, poloxamer 338, poloxamer 118, poloxamine 1107 or poloxamine 1307.
10. The method of claim 5 , wherein said at least one purified inverse thermosensitive polymer is poloxamer 407.
11. The method of claim 5 , wherein said composition comprises at least one purified inverse thermosensitive polymer selected from the group consisting of purified poloxamers and purified poloxamines.
12. The method of claim 5 , wherein said composition has a transition temperature of between about 10° C. and about 40° C.
13. The method of claim 5 , wherein said composition has a transition temperature of between about 15° C. and about 30° C.
14. The method of claim 5 , wherein the volume of said composition at physiological temperature is about 80% to about 120% of its volume below its transition temperature.
15. The method of claim 5 , wherein the volume of said composition at physiological temperature is about 80% to about 120% of its volume below its transition temperature; and said composition has a transition temperature of between about 10° C. and about 40° C.
16. The method of claim 5 , wherein the volume of said composition at physiological temperature is about 80% to about 120% of its volume below its transition temperature; and said composition has a transition temperature of between about 15° C. and about 30° C.
17. The method of claim 5 , wherein the volume of said composition at physiological temperature is about 80% to about 120% of its volume below its transition temperature; said composition has a transition temperature of between about 10° C. and about 40° C.; and said composition comprises at least one purified inverse thermosensitive polymer selected from the group consisting of poloxamers and poloxamines.
18. The method of claim 5 , wherein the volume of said composition at physiological temperature is about 80% to about 120% of its volume below its transition temperature; said composition has a transition temperature of between about 15° C. and about 30° C.; and said composition comprises at least one purified inverse thermosensitive polymer selected from the group consisting of poloxamers and poloxamines.
19. The method of claim 5 , wherein said composition comprises about 50% to about 35% of said inverse thermosensitive polymer.
20. The method of claim 5 , wherein said composition comprises about boo to about 30% of said inverse thermosensitive polymer.
21. The method of claim 5 , wherein the inverse thermosensitive polymer has a polydispersity index from about 1.5 to about 1.0.
22. The method of claim 5 , wherein the inverse thermosensitive polymer has a polydispersity index from about 1.2 to about 1.0.
23. The method of claim 5 , wherein said surgical site is at or proximal to a hemorrhage, cancerous tissue, tumor, or organ.
24. The method of claim 5 , wherein said surgical procedure comprises anastomosis.
25. The method of claim 24 , wherein said anastomosis comprises connecting a first vessel and a second vessel.
26. The method of claim 25 , wherein said connecting a first vessel and a second vessel comprises suturing, laser welding or laser soldering.
27. The method of claim 24 , wherein said anastomosis is selected from the group consisting of end-to-end anastomosis, side-to-end anastomosis and side-to-side anastomosis.
28. The method of claim 5 , wherein said occlusion reduces bleeding during said surgical procedure.
29. The method of claim 5 , wherein said occlusion enables controlled ischemic preconditioning of said surgical site.
30. The method of claim 5 , wherein said occlusion is at or proximal to an incision site for minimally invasive surgery and decreases bleeding through the incision.
31. The method of claim 5 , wherein said composition occludes said vascular site for less than about one hour.
32. The method of claim 5 , wherein said composition further comprises a contrast-enhancing agent.
33. The method of claim 32 , wherein said contrast-enhancing agent is selected from the group consisting of radiopaque materials, paramagnetic materials, heavy atoms, transition metals, lanthanides, actinides, dyes, and radionuclide-containing materials.
34. The method of claim 5 , wherein said composition further comprises a biologically active agent.
35. The method of claim 34 , wherein the biologically active agent is selected from the group consisting of antiinflammatories, antibiotics, antimicrobials, chemotherapeutics, antivirals, analgesics, antiproliferatives, plasmids, DNA and RNA.
36. The method of claim 5 , wherein said mammal is a human.
37. The method of claim 5 , wherein said composition is introduced to said vasculature through a percutaneous access device.
38. The method of claim 5 , wherein said composition is introduced to said vasculature using a catheter.
39. The method of claim 5 , wherein said composition is introduced to said vasculature using a syringe.
40. The method of claim 5 , further comprising the step of:
injecting an aqueous solution at or proximal to the occlusion site, thereby dissolving said occlusion.
41. The method of claim 40 , wherein said composition comprises at least one purified inverse thermosensitive polymer selected from the group consisting of poloxamers and poloxamines.
42. The method of claim 40 , wherein said at least one purified inverse thermosensitive polymer is selected from the group consisting of poloxamer 407, poloxamer 338, poloxamer 118, poloxamine 1107 or poloxamine 1307.
43. The method of claim 40 , wherein said at least one purified inverse thermosensitive polymer is poloxamer 407.
44. The method of claim 5 , further comprising the step of:
cooling the occlusion site, thereby liquefying the gel and dissolving said occlusion.
45. The method of claim 44 , said occlusion site is cooled by using a cold aqueous solution or ice.
46. The method of claim 44 , wherein said composition comprises at least one purified inverse thermosensitive polymer selected from the group consisting of poloxamers and poloxamines.
47. The method of claim 44 , wherein said at least one purified inverse thermosensitive polymer is selected from the group consisting of poloxamer 407, poloxamer 338, poloxamer 118, poloxamine 1107 or poloxamine 1307.
48. The method of claim 44 , wherein said at least one purified inverse thermosensitive polymer is poloxamer 407.
49. The method of claim 5 , wherein said composition comprises at least one purified inverse thermosensitive polymer selected from the group consisting of poloxamers and poloxamines; and said surgical procedure comprises anastomosis.
50. The method of claim 5 , wherein said at least one purified inverse thermosensitive polymer is selected from the group consisting of poloxamer 407, poloxamer 338, poloxamer 118, poloxamine 1107 or poloxamine 1307; and said surgical procedure comprises anastomosis.
51. The method of claim 5 , wherein said at least one purified inverse thermosensitive polymer is poloxamer 407; and said surgical procedure comprises anastomosis.